Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma

The development of BRAF and MEK inhibitors (BRAFi/MEKi) has led to major advances in melanoma treatment. However, the emergence of resistance mechanisms limits the benefit duration and a complete response occurs in less than 20% of patients receiving BRAFi ± MEKi. In this study, we evaluated the imp...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Transl Oncol
Main Authors: Reger de Moura, Coralie, Vercellino, Laetitia, Jouenne, Fanélie, Baroudjian, Barouyr, Sadoux, Aurélie, Louveau, Baptiste, Delyon, Julie, Serror, Kevin, Goldwirt, Lauriane, Merlet, Pascal, Bouquet, Fanny, Battistella, Maxime, Lebbé, Céleste, Mourah, Samia
Formato: Artigo
Idioma:Inglês
Publicado: Neoplasia Press 2019
Assuntos:
Original article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6931208/
https://ncbi.nlm.nih.gov/pubmed/31874374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.10.003
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares